Egnach, June 2, 2025 – The tinnitus therapy device tinniwell has recorded a significant increase in usage. Compared to May of the previous year, the number of devices used has risen by over 900 %.

“This development shows that our approach of offering affected individuals a flexible option for use is garnering great interest,” says Anke Rauterkus, member of the board of directors of Resaphene. “More and more people are recognizing the benefits of tinniwell in their daily lives.”

Current studies underscore the relevance of the topic of tinnitus: A European-wide survey found that almost 15 % of adults in Europe suffer from tinnitus. Furthermore, the renowned scientist Prof. Dr. Pim van Dijk was awarded the Tinnitus & Hearing Research Prize in December 2024. His neuroscientific study examines the link between tinnitus and abnormal GABAergic inhibition in the brain, opening new perspectives for treatment.

++ About Resaphene Suisse AG

Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company founded in 2015, which has been marketing a tinnitus therapy device under the name tinniwell since 2016.

++ Contact for inquiries:

Resaphene Suisse AG
Ms. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland

T. +41 71 510 07 24
a.rauterkus@resaphene.ch